Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Non‐replacement therapy"'
Autor:
Mancuso ME; Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Milan 20089, Italy. Electronic address: mariaelisa_mancuso@libero.it.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2024 Dec; Vol. 11 (12), pp. e880-e881.
Autor:
Marietta M; Haematology Unit, Azienda Ospedaliero-Universitaria di Modena, Italy, Luppi M; Haematology Unit, Azienda Ospedaliero-Universitaria di Modena, Italy; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
Publikováno v:
Blood transfusion = Trasfusione del sangue [Blood Transfus] 2018 Sep; Vol. 16 (5). Date of Electronic Publication: 2018 Mar 02.
Autor:
Marco, Marietta, Mario, Luppi
One of the most challenging issues facing us in the treatment of haemophilia is the development of alloantibodies against infused factor VIII (FVIII) or factor IX (FIX). Inhibitors render factor replacement therapy ineffective, exposing patients to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a0fd6feb45ec0acb2eb098934d7c7d5b
https://europepmc.org/articles/PMC6125232/
https://europepmc.org/articles/PMC6125232/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Biologics: Targets & Therapy, Vol Volume 15, Pp 221-235 (2021)
Emanuela Marchesini,1 Massimo Morfini,2 Leonard Valentino3,4 1Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Perugia, Italy; 2Italian Association of Haemophilia Centres (AICE), Naples, Italy; 3National Hemophilia Foun
Externí odkaz:
https://doaj.org/article/c6d879e97ddb45358283ae5bbce72a6d
Autor:
Gili Kenet, Kaan Kavakli, Jan Blatný, Christoph Male, Karin Fijnvandraat, Christoph Königs, Maria Elisa Mancuso
Publikováno v:
Haemophilia. 27:889-896
Introduction For children with haemophilia, early initiation of prophylaxis is crucial to prevent life-threatening bleeds and maintain joint health throughout life. Options for prophylaxis have recently increased from replacement therapy with standar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597ac69c8a3f30c690d4928e2c486a1b
https://doi.org/10.1111/hae.14412
https://doi.org/10.1111/hae.14412
Autor:
Mancuso, Maria Elisa1 (AUTHOR), Male, Christoph2 (AUTHOR), Kenet, Gili3 (AUTHOR), Kavakli, Kaan4 (AUTHOR), Königs, Christoph5 (AUTHOR), Blatný, Jan6 (AUTHOR), Fijnvandraat, Karin7 (AUTHOR) c.j.fijnvandraat@amsterdamumc.nl
Publikováno v:
Haemophilia. Nov2021, Vol. 27 Issue 6, p889-896. 8p. 1 Diagram, 1 Chart.
Autor:
Antonio Coppola, Massimo Franchini, Giovanni Pappagallo, Alessandra Borchiellini, Raimondo De Cristofaro, Angelo Claudio Molinari, Rita Carlotta Santoro, Cristina Santoro, Annarita Tagliaferri
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 3; Pages: 801
Journal of Clinical Medicine, Vol 11, Iss 801, p 801 (2022)
Journal of Clinical Medicine, Vol 11, Iss 801, p 801 (2022)
Background. Regular treatment to prevent bleeding and consequent joint deterioration (prophylaxis) is the standard of care for persons with severe hemophilia A, traditionally based on intravenous infusions of the deficient clotting FVIII concentrates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef23804bc2de4e1fe4e55ef479ba03ac
Autor:
Versloot, Olav1,2 (AUTHOR) o.versloot@umcutrecht.nl, Kemler, Ellen3 (AUTHOR), Blokzijl, Johan1 (AUTHOR), Timmer, Merel1 (AUTHOR), Schuuring, Marleen4 (AUTHOR), van Galen, Karin P. M.1 (AUTHOR), Kremer Hovinga, Idske Cornelia L.1 (AUTHOR), van der Valk, Paul R.1 (AUTHOR), van Vulpen, Lize F. D.1 (AUTHOR), Schutgens, Roger E. G.1 (AUTHOR), van Koppenhagen, Casper F.5 (AUTHOR), van der Net, Janjaap4 (AUTHOR), Fischer, Kathelijn1 (AUTHOR)
Publikováno v:
Haemophilia. Jul2023, Vol. 29 Issue 4, p1013-1023. 11p. 3 Diagrams, 4 Charts, 2 Graphs.
Publikováno v:
Biologics : Targets & Therapy
Progress in hemophilia therapy has been remarkable in the first 20 years of the third millennium, but the innovation began with the description the fractionation of plasma in 1946. The first concentrates followed the discovery of FVIII in the cryopre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb174d070a4b1b2907c531aadebf9ca3
http://europepmc.org/articles/PMC8214539
http://europepmc.org/articles/PMC8214539